1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Cephalon moves into biologics with Arana acquisition

 
• By John Davis

Cephalon has completed its acquisition of all the outstanding ordinary shares of the Australian biotech firm Arana Therapeutics. It acquired a controlling stake in the company in May.

Cephalon has completed its acquisition of all the outstanding ordinary shares of the Australian biotech firm Arana Therapeutics. It acquired a controlling stake in the company in May.

The acquisition marks Cephalon's entry into the biologics business. Arana, now a wholly owned subsidiary of Cephalon, has a domain...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapeutic Category

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?